{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:04:11Z","timestamp":1790013851843,"version":"4.0.1"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"DOI":"10.1038\/s41574-026-01302-4","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:14:47Z","timestamp":1790007287000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The causes of cachexia: key signals and the brain"],"prefix":"10.1038","author":[{"given":"Aideen","family":"Daly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4447-3390","authenticated-orcid":false,"given":"Su Lei","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2594-7463","authenticated-orcid":false,"given":"Anthony P.","family":"Coll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"1302_CR1","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/nrc3829","volume":"14","author":"JM Argil\u00e9s","year":"2014","unstructured":"Argil\u00e9s, J. M., Busquets, S., Stemmler, B. & L\u00f3pez-Soriano, F. J. Cancer cachexia: understanding the molecular basis. Nat. Rev. Cancer 14, 754\u2013762 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"1302_CR2","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1016\/j.cell.2023.03.028","volume":"186","author":"M Ferrer","year":"2023","unstructured":"Ferrer, M. et al. Cachexia: a systemic consequence of progressive, unresolved disease. Cell 186, 1824\u20131845 (2023).","journal-title":"Cell"},{"key":"1302_CR3","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon, K. et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 12, 489\u2013495 (2011).","journal-title":"Lancet Oncol."},{"key":"1302_CR4","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/nature05026","volume":"443","author":"GJ Morton","year":"2006","unstructured":"Morton, G. J., Cummings, D. E., Baskin, D. G., Barsh, G. S. & Schwartz, M. W. Central nervous system control of food intake and body weight. Nature 443, 289\u2013295 (2006).","journal-title":"Nature"},{"key":"1302_CR5","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41576-021-00414-z","volume":"23","author":"RJF Loos","year":"2022","unstructured":"Loos, R. J. F. & Yeo, G. S. H. The genetics of obesity: from discovery to biology. Nat. Rev. Genet. 23, 120\u2013133 (2022).","journal-title":"Nat. Rev. Genet."},{"key":"1302_CR6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.cell.2015.03.008","volume":"161","author":"AA van der Klaauw","year":"2015","unstructured":"van der Klaauw, A. A. & Farooqi, I. S. The hunger genes: pathways to obesity. Cell 161, 119\u2013132 (2015).","journal-title":"Cell"},{"key":"1302_CR7","doi-asserted-by":"publisher","first-page":"R173","DOI":"10.1530\/ERC-17-0036","volume":"24","author":"GK Dimitriadis","year":"2017","unstructured":"Dimitriadis, G. K. et al. Paraneoplastic endocrine syndromes. Endocr. Relat. Cancer 24, R173\u2013R190 (2017).","journal-title":"Endocr. Relat. Cancer"},{"key":"1302_CR8","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1038\/s42255-024-01167-9","volume":"6","author":"M Berriel Diaz","year":"2024","unstructured":"Berriel Diaz, M., Rohm, M. & Herzig, S. Cancer cachexia: multilevel metabolic dysfunction. Nat. Metab. 6, 2222\u20132245 (2024).","journal-title":"Nat. Metab."},{"key":"1302_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2016.3","volume":"5","author":"PE Porporato","year":"2016","unstructured":"Porporato, P. E. Understanding cachexia as a cancer metabolism syndrome. Oncogenesis 5, e200 (2016).","journal-title":"Oncogenesis"},{"key":"1302_CR10","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/s41571-023-00734-5","volume":"20","author":"JM Argil\u00e9s","year":"2023","unstructured":"Argil\u00e9s, J. M., L\u00f3pez-Soriano, F. J., Stemmler, B. & Busquets, S. Cancer-associated cachexia - understanding the tumour macroenvironment and microenvironment to improve management. Nat. Rev. Clin. Oncol. 20, 250\u2013264 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1302_CR11","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_389942","volume":"43","author":"KC Kadakia","year":"2023","unstructured":"Kadakia, K. C., Hamilton-Reeves, J. M. & Baracos, V. E. Current therapeutic targets in cancer cachexia: a pathophysiologic approach. Am. Soc. Clin. Oncol. Educ. Book 43, e389942 (2023).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"1302_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100092","volume":"6","author":"J Arends","year":"2021","unstructured":"Arends, J. et al. Cancer cachexia in adult patients: ESMO clinical practice guidelines. ESMO Open 6, 100092 (2021).","journal-title":"ESMO Open"},{"key":"1302_CR13","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1200\/JCO.23.01280","volume":"41","author":"EJ Roeland","year":"2023","unstructured":"Roeland, E. J. et al. Cancer cachexia: ASCO guideline rapid recommendation update. J. Clin. Oncol. 41, 4178\u20134179 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1302_CR14","doi-asserted-by":"publisher","first-page":"17105","DOI":"10.1038\/nrdp.2017.105","volume":"4","author":"VE Baracos","year":"2018","unstructured":"Baracos, V. E., Martin, L., Korc, M., Guttridge, D. C. & Fearon, K. C. H. Cancer-associated cachexia. Nat. Rev. Dis. Primer 4, 17105 (2018).","journal-title":"Nat. Rev. Dis. Primer"},{"key":"1302_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/jcsm.13109","volume":"14","author":"I Pototschnig","year":"2023","unstructured":"Pototschnig, I. et al. Interleukin-6 initiates muscle- and adipose tissue wasting in a novel C57BL\/6 model of cancer-associated cachexia. J. Cachexia Sarcopenia Muscle 14, 93\u2013107 (2023).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"1302_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0102436","volume":"9","author":"K Ando","year":"2014","unstructured":"Ando, K. et al. Tocilizumab, a proposed therapy for the cachexia of interleukin6-expressing lung cancer. PLoS ONE 9, e102436 (2014).","journal-title":"PLoS ONE"},{"key":"1302_CR17","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190450","volume":"218","author":"JE Rupert","year":"2021","unstructured":"Rupert, J. E. et al. Tumor-derived IL-6 and trans-signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia. J. Exp. Med. 218, e20190450 (2021).","journal-title":"J. Exp. Med."},{"key":"1302_CR18","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190347","volume":"217","author":"S Kang","year":"2020","unstructured":"Kang, S., Narazaki, M., Metwally, H. & Kishimoto, T. Historical overview of the interleukin-6 family cytokine. J. Exp. Med. 217, e20190347 (2020).","journal-title":"J. Exp. Med."},{"key":"1302_CR19","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson, D. E., O\u2019Keefe, R. A. & Grandis, J. R. Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat. Rev. Clin. Oncol. 15, 234\u2013248 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1302_CR20","doi-asserted-by":"publisher","first-page":"11553","DOI":"10.1007\/s13277-016-5098-7","volume":"37","author":"N Kumari","year":"2016","unstructured":"Kumari, N., Dwarakanath, B. S., Das, A. & Bhatt, A. N. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. 37, 11553\u201311572 (2016).","journal-title":"Tumour Biol."},{"key":"1302_CR21","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/SPC.0000000000000091","volume":"8","author":"AA Narsale","year":"2014","unstructured":"Narsale, A. A. & Carson, J. A. Role of interleukin-6 in cachexia: therapeutic implications. Curr. Opin. Support Palliat. Care 8, 321\u2013327 (2014).","journal-title":"Curr. Opin. Support Palliat. Care"},{"key":"1302_CR22","first-page":"4009","volume":"291","author":"S Agca","year":"2024","unstructured":"Agca, S. & Kir, S. The role of interleukin-6 family cytokines in cancer cachexia. FEBS J. 291, 4009\u20134023 (2024).","journal-title":"FEBS J."},{"key":"1302_CR23","doi-asserted-by":"publisher","first-page":"R393","DOI":"10.1152\/ajpregu.00716.2007","volume":"294","author":"KA Baltgalvis","year":"2008","unstructured":"Baltgalvis, K. A. et al. Interleukin-6 and cachexia in ApcMin\/+ mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 294, R393\u2013R401 (2008).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"1302_CR24","doi-asserted-by":"publisher","first-page":"67","DOI":"10.21037\/apm.2018.07.06","volume":"8","author":"BL Prado","year":"2019","unstructured":"Prado, B. L. & Qian, Y. Anti-cytokines in the treatment of cancer cachexia. Ann. Palliat. Med. 8, 67\u201379 (2019).","journal-title":"Ann. Palliat. Med."},{"key":"1302_CR25","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1517\/14712598.2011.627850","volume":"11","author":"TJ Bayliss","year":"2011","unstructured":"Bayliss, T. J., Smith, J. T., Schuster, M., Dragnev, K. H. & Rigas, J. R. A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin. Biol. Ther. 11, 1663\u20131668 (2011).","journal-title":"Expert Opin. Biol. Ther."},{"key":"1302_CR26","doi-asserted-by":"publisher","first-page":"7622","DOI":"10.1200\/jco.2010.28.15_suppl.7622","volume":"28","author":"JR Rigas","year":"2010","unstructured":"Rigas, J. R. et al. Effect of ALD518, a humanized anti-IL-6 antibody, on lean body mass loss and symptoms in patients with advanced non-small cell lung cancer (NSCLC): results of a phase II randomized, double-blind safety and efficacy trial. J. Clin. Oncol. 28, 7622 (2010).","journal-title":"J. Clin. Oncol."},{"key":"1302_CR27","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1002\/jcsm.13638","volume":"15","author":"Y Du","year":"2024","unstructured":"Du, Y. et al. Tocilizumab for advanced non-small-cell lung cancer with concomitant cachexia: an observational study. J. Cachexia Sarcopenia Muscle 15, 2815\u20132825 (2024).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"1302_CR28","doi-asserted-by":"publisher","first-page":"5372","DOI":"10.1158\/0008-5472.CAN-15-3152","volume":"76","author":"JL Chen","year":"2016","unstructured":"Chen, J. L. et al. Differential effects of IL6 and activin a in the development of cancer-associated cachexia. Cancer Res. 76, 5372\u20135382 (2016).","journal-title":"Cancer Res."},{"key":"1302_CR29","doi-asserted-by":"publisher","first-page":"R1165","DOI":"10.1152\/ajpregu.2000.279.4.R1165","volume":"279","author":"YP Li","year":"2000","unstructured":"Li, Y. P. & Reid, M. B. NF-kB mediates the protein loss induced by TNF-\u03b1 in differentiated skeletal muscle myotubes. Am. J. Physiol. Regul. Integr. Comp. Physiol 279, R1165\u2013R1170 (2000).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol"},{"key":"1302_CR30","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.lfs.2016.11.033","volume":"170","author":"HJ Patel","year":"2017","unstructured":"Patel, H. J. & Patel, B. M. TNF-\u03b1 and cancer cachexia: molecular insights and clinical implications. Life Sci. 170, 56\u201363 (2017).","journal-title":"Life Sci."},{"key":"1302_CR31","first-page":"4881","volume":"55","author":"J Nakashima","year":"1995","unstructured":"Nakashima, J., Tachibana, M., Ueno, M., Baba, S. & Tazaki, H. Tumor necrosis factor and coagulopathy in patients with prostate cancer. Cancer Res. 55, 4881\u20134885 (1995).","journal-title":"Cancer Res."},{"key":"1302_CR32","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/rr67","volume":"2","author":"MB Reid","year":"2001","unstructured":"Reid, M. B. & Li, Y. P. Tumor necrosis factor-alpha and muscle wasting: a cellular perspective. Respir. Res. 2, 269\u2013272 (2001).","journal-title":"Respir. Res."},{"key":"1302_CR33","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.bbi.2015.04.001","volume":"49","author":"P Feng","year":"2015","unstructured":"Feng, P. et al. Regulation of bitter taste responses by tumor necrosis factor. Brain Behav. Immun. 49, 32\u201342 (2015).","journal-title":"Brain Behav. Immun."},{"key":"1302_CR34","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1007\/s001250050350","volume":"38","author":"H Hauner","year":"1995","unstructured":"Hauner, H., Petruschke, T., Russ, M., R\u00f6hrig, K. & Eckel, J. Effects of tumour necrosis factor alpha (TNF\u03b1) on glucose transport and lipid metabolism of newly-differentiated human fat cells in cell culture. Diabetologia 38, 764\u2013771 (1995).","journal-title":"Diabetologia"},{"key":"1302_CR35","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1002\/cncr.22944","volume":"110","author":"A Jatoi","year":"2007","unstructured":"Jatoi, A. et al. A placebo-controlled double blind trial of etanercept for the cancer anorexia\/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group. Cancer 110, 1396\u20131403 (2007).","journal-title":"Cancer"},{"key":"1302_CR36","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.lungcan.2009.06.020","volume":"68","author":"A Jatoi","year":"2010","unstructured":"Jatoi, A. et al. A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and\/or poor performance non-small cell lung cancer patients (N01C9). Lung Cancer 68, 234\u2013239 (2010).","journal-title":"Lung Cancer"},{"key":"1302_CR37","first-page":"18","volume":"6","author":"B Wiedenmann","year":"2008","unstructured":"Wiedenmann, B. et al. A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. J. Support. Oncol. 6, 18\u201325 (2008).","journal-title":"J. Support. Oncol."},{"key":"1302_CR38","doi-asserted-by":"publisher","first-page":"11514","DOI":"10.1073\/pnas.94.21.11514","volume":"94","author":"MR Bootcov","year":"1997","unstructured":"Bootcov, M. R. et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-\u03b2 superfamily. Proc. Natl Acad. Sci. USA 94, 11514\u201311519 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1302_CR39","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/nm.4392","volume":"23","author":"SE Mullican","year":"2017","unstructured":"Mullican, S. E. et al. GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates. Nat. Med. 23, 1150\u20131157 (2017).","journal-title":"Nat. Med."},{"key":"1302_CR40","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/nm.4393","volume":"23","author":"PJ Emmerson","year":"2017","unstructured":"Emmerson, P. J. et al. The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL. Nat. Med. 23, 1215\u20131219 (2017).","journal-title":"Nat. Med."},{"key":"1302_CR41","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1038\/nm.4394","volume":"23","author":"L Yang","year":"2017","unstructured":"Yang, L. et al. GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand. Nat. Med. 23, 1158\u20131166 (2017).","journal-title":"Nat. Med."},{"key":"1302_CR42","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.cmet.2017.10.017","volume":"26","author":"S O\u2019Rahilly","year":"2017","unstructured":"O\u2019Rahilly, S. GDF15-from biomarker to allostatic hormone. Cell Metab. 26, 807\u2013808 (2017).","journal-title":"Cell Metab."},{"key":"1302_CR43","doi-asserted-by":"publisher","first-page":"bnaa007","DOI":"10.1210\/endrev\/bnaa007","volume":"41","author":"SM Lockhart","year":"2020","unstructured":"Lockhart, S. M., Saudek, V. & O\u2019Rahilly, S. GDF15: a hormone conveying somatic distress to the brain. Endocr. Rev. 41, bnaa007 (2020).","journal-title":"Endocr. Rev."},{"key":"1302_CR44","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1146\/annurev-physiol-022020-045449","volume":"83","author":"SN Breit","year":"2021","unstructured":"Breit, S. N., Brown, D. A. & Tsai, V. W. The GDF15-GFRAL pathway in health and metabolic disease: friend or foe? Annu. Rev. Physiol. 83, 127\u2013151 (2021).","journal-title":"Annu. Rev. Physiol."},{"key":"1302_CR45","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cmet.2018.12.016","volume":"29","author":"S Patel","year":"2019","unstructured":"Patel, S. et al. GDF15 provides an endocrine signal of nutritional stress in mice and humans. Cell Metab. 29, 707\u2013718 (2019).","journal-title":"Cell Metab."},{"key":"1302_CR46","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2106868118","volume":"118","author":"I Cimino","year":"2021","unstructured":"Cimino, I. et al. Activation of the hypothalamic\u2013pituitary\u2013adrenal axis by exogenous and endogenous GDF15. Proc. Natl Acad. Sci. USA 118, e2106868118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1302_CR47","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.55164","volume":"9","author":"AA Worth","year":"2020","unstructured":"Worth, A. A. et al. The cytokine GDF15 signals through a population of brainstem cholecystokinin neurons to mediate anorectic signalling. eLife 9, e55164 (2020).","journal-title":"eLife"},{"key":"1302_CR48","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1038\/s42255-024-01135-3","volume":"6","author":"AM Gurtan","year":"2024","unstructured":"Gurtan, A. M. et al. Identification and characterization of human GDF15 knockouts. Nat. Metab. 6, 1913\u20131921 (2024).","journal-title":"Nat. Metab."},{"key":"1302_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-578","volume":"14","author":"X Wang","year":"2014","unstructured":"Wang, X. et al. Macrophage inhibitory cytokine 1 (MIC-1\/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma. BMC Cancer 14, 578 (2014).","journal-title":"BMC Cancer"},{"key":"1302_CR50","doi-asserted-by":"publisher","first-page":"dju016","DOI":"10.1093\/jnci\/dju016","volume":"106","author":"RS Mehta","year":"2014","unstructured":"Mehta, R. S. et al. A prospective study of macrophage inhibitory cytokine-1 (MIC-1\/GDF15) and risk of colorectal cancer. J. Natl Cancer Inst. 106, dju016 (2014).","journal-title":"J. Natl Cancer Inst."},{"key":"1302_CR51","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/s41591-023-02232-8","volume":"29","author":"O Al-Sawaf","year":"2023","unstructured":"Al-Sawaf, O. et al. Body composition and lung cancer-associated cachexia in TRACERx. Nat. Med. 29, 846\u2013858 (2023).","journal-title":"Nat. Med."},{"key":"1302_CR52","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/nm1677","volume":"13","author":"H Johnen","year":"2007","unstructured":"Johnen, H. et al. Tumor-induced anorexia and weight loss are mediated by the TGF-\u03b2 superfamily cytokine MIC-1. Nat. Med. 13, 1333\u20131340 (2007).","journal-title":"Nat. Med."},{"key":"1302_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107543","volume":"31","author":"T Borner","year":"2020","unstructured":"Borner, T. et al. GDF15 induces an aversive visceral malaise state that drives anorexia and weight loss. Cell Rep. 31, 107543 (2020).","journal-title":"Cell Rep."},{"key":"1302_CR54","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.cmet.2019.12.004","volume":"31","author":"T Borner","year":"2020","unstructured":"Borner, T. et al. GDF15 induces anorexia through nausea and emesis. Cell Metab. 31, 351\u2013362 (2020).","journal-title":"Cell Metab."},{"key":"1302_CR55","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41562-024-02078-1","volume":"9","author":"C Shen","year":"2025","unstructured":"Shen, C. et al. Plasma proteomic signatures of social isolation and loneliness associated with morbidity and mortality. Nat. Hum. Behav. 9, 569\u2013583 (2025).","journal-title":"Nat. Hum. Behav."},{"key":"1302_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21309-x","volume":"12","author":"AB Klein","year":"2021","unstructured":"Klein, A. B. et al. Pharmacological but not physiological GDF15 suppresses feeding and the motivation to exercise. Nat. Commun. 12, 1041 (2021).","journal-title":"Nat. Commun."},{"key":"1302_CR57","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41586-023-06249-4","volume":"619","author":"D Wang","year":"2023","unstructured":"Wang, D. et al. GDF15 promotes weight loss by enhancing energy expenditure in muscle. Nature 619, 143\u2013150 (2023).","journal-title":"Nature"},{"key":"1302_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111947","volume":"42","author":"JY Kim-Muller","year":"2023","unstructured":"Kim-Muller, J. Y. et al. GDF15 neutralization restores muscle function and physical performance in a mouse model of cancer cachexia. Cell Rep. 42, 111947 (2023).","journal-title":"Cell Rep."},{"key":"1302_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-68702-y","volume":"17","author":"J Yu","year":"2026","unstructured":"Yu, J. et al. Cancer cachexia in STK11\/LKB1-mutated non-small cell lung cancer is dependent on tumor-secreted GDF15. Nat. Commun. 17, 2182 (2026).","journal-title":"Nat. Commun."},{"key":"1302_CR60","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1158\/1078-0432.CCR-23-1631","volume":"30","author":"J Crawford","year":"2024","unstructured":"Crawford, J. et al. A phase Ib first-in-patient study assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of ponsegromab in participants with cancer and cachexia. Clin. Cancer Res. 30, 489\u2013497 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1302_CR61","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1056\/NEJMoa2409515","volume":"391","author":"JD Groarke","year":"2024","unstructured":"Groarke, J. D. et al. Ponsegromab for the treatment of cancer cachexia. N. Engl. J. Med. 391, 2291\u20132303 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1302_CR62","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1158\/2767-9764.CRC-24-0565","volume":"5","author":"BA Carneiro","year":"2025","unstructured":"Carneiro, B. A. et al. First-in-human study to evaluate the safety and efficacy of anti-GDF15 antibody AZD8853 in patients with advanced\/metastatic solid tumors. Cancer Res. Commun. 5, 896\u2013905 (2025).","journal-title":"Cancer Res. Commun."},{"key":"1302_CR63","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1111\/cas.15491","volume":"113","author":"K Hanada","year":"2022","unstructured":"Hanada, K. et al. Combination therapy with anamorelin and a myostatin inhibitor is advantageous for cancer cachexia in a mouse model. Cancer Sci. 113, 3547\u20133557 (2022).","journal-title":"Cancer Sci."},{"key":"1302_CR64","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.70312","volume":"17","author":"DM Breen","year":"2026","unstructured":"Breen, D. M. et al. Targeting cancer cachexia: a mechanistic evaluation of anti-GDF-15 antibody-based combination therapies. J. Cachexia Sarcopenia Muscle 17, e70312 (2026).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"1302_CR65","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.cmet.2020.10.023","volume":"32","author":"DM Breen","year":"2020","unstructured":"Breen, D. M. et al. GDF-15 neutralization alleviates platinum-based chemotherapy-induced emesis, anorexia, and weight loss in mice and nonhuman primates. Cell Metab. 32, 938\u2013950 (2020).","journal-title":"Cell Metab."},{"key":"1302_CR66","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1002\/jcsm.13219","volume":"14","author":"BY Lee","year":"2023","unstructured":"Lee, B. Y. et al. GDNF family receptor \u03b1-like antagonist antibody alleviates chemotherapy-induced cachexia in melanoma-bearing mice. J. Cachexia Sarcopenia Muscle 14, 1441\u20131453 (2023).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"1302_CR67","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1038\/s41586-024-08305-z","volume":"637","author":"I Melero","year":"2025","unstructured":"Melero, I. et al. Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. Nature 637, 1218\u20131227 (2025).","journal-title":"Nature"},{"key":"1302_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39817-3","volume":"14","author":"M Haake","year":"2023","unstructured":"Haake, M. et al. Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment. Nat. Commun. 14, 4253 (2023).","journal-title":"Nat. Commun."},{"key":"1302_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2024.102070","volume":"91","author":"C Hes","year":"2025","unstructured":"Hes, C. et al. GDNF family receptor \u03b1-like (GFRAL) expression is restricted to the caudal brainstem. Mol. Metab. 91, 102070 (2025).","journal-title":"Mol. Metab."},{"key":"1302_CR70","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41590-025-02406-1","volume":"27","author":"JK Sonner","year":"2026","unstructured":"Sonner, J. K. et al. A GDF-15\u2013GFRAL axis controls autoimmune T cell responses during neuroinflammation. Nat. Immunol. 27, 503\u2013515 (2026).","journal-title":"Nat. Immunol."},{"key":"1302_CR71","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41574-023-00855-y","volume":"19","author":"P Sweeney","year":"2023","unstructured":"Sweeney, P., Gimenez, L. E., Hernandez, C. C. & Cone, R. D. Targeting the central melanocortin system for the treatment of metabolic disorders. Nat. Rev. Endocrinol. 19, 507\u2013519 (2023).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1302_CR72","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ejphar.2010.12.025","volume":"660","author":"BJ Renquist","year":"2011","unstructured":"Renquist, B. J., Lippert, R. N., Sebag, J. A., Ellacott, K. L. & Cone, R. D. Physiological roles of the melanocortin MC3 receptor. Eur. J. Pharmacol. 660, 13\u201320 (2011).","journal-title":"Eur. J. Pharmacol."},{"key":"1302_CR73","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41586-024-08504-8","volume":"639","author":"JA Tadross","year":"2025","unstructured":"Tadross, J. A. et al. A comprehensive spatio-cellular map of the human hypothalamus. Nature 639, 708\u2013716 (2025).","journal-title":"Nature"},{"key":"1302_CR74","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1172\/JCI9397","volume":"106","author":"IS Farooqi","year":"2000","unstructured":"Farooqi, I. S. et al. Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. J. Clin. Invest. 106, 271\u2013279 (2000).","journal-title":"J. Clin. Invest."},{"key":"1302_CR75","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1172\/JCI9238","volume":"106","author":"C Vaisse","year":"2000","unstructured":"Vaisse, C. et al. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J. Clin. Invest. 106, 253\u2013262 (2000).","journal-title":"J. Clin. Invest."},{"key":"1302_CR76","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/s41591-021-01349-y","volume":"27","author":"KH Wade","year":"2021","unstructured":"Wade, K. H. et al. Loss-of-function mutations in the melanocortin 4 receptor in a UK birth cohort. Nat. Med. 27, 1088\u20131096 (2021).","journal-title":"Nat. Med."},{"key":"1302_CR77","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fnins.2017.00128","volume":"11","author":"AA Butler","year":"2017","unstructured":"Butler, A. A. et al. A life without hunger: the ups (and downs) to modulating melanocortin-3 receptor signaling. Front. Neurosci. 11, 128 (2017).","journal-title":"Front. Neurosci."},{"key":"1302_CR78","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/s41586-021-04088-9","volume":"599","author":"BYH Lam","year":"2021","unstructured":"Lam, B. Y. H. et al. MC3R links nutritional state to childhood growth and the timing of puberty. Nature 599, 436\u2013441 (2021).","journal-title":"Nature"},{"key":"1302_CR79","doi-asserted-by":"publisher","first-page":"102301","DOI":"10.1016\/j.molmet.2025.102301","volume":"103","author":"K Duckett","year":"2026","unstructured":"Duckett, K. et al. Cross-species studies implicate the melanocortin 3 receptor more strongly in the control of pubertal development than energy balance. Mol. Metab. 103, 102301 (2026).","journal-title":"Mol. Metab."},{"key":"1302_CR80","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1002\/cne.25379","volume":"530","author":"MN Bedenbaugh","year":"2022","unstructured":"Bedenbaugh, M. N. et al. Organization of neural systems expressing melanocortin-3 receptors in the mouse brain: evidence for sexual dimorphism. J. Comp. Neurol. 530, 2835\u20132851 (2022).","journal-title":"J. Comp. Neurol."},{"key":"1302_CR81","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd6434","volume":"13","author":"P Sweeney","year":"2021","unstructured":"Sweeney, P. et al. The melanocortin-3 receptor is a pharmacological target for the regulation of anorexia. Sci. Transl. Med. 13, eabd6434 (2021).","journal-title":"Sci. Transl. Med."},{"key":"1302_CR82","doi-asserted-by":"publisher","DOI":"10.1172\/JCI178250","volume":"134","author":"NS Dahir","year":"2024","unstructured":"Dahir, N. S. et al. Subthreshold activation of the melanocortin system causes generalized sensitization to anorectic agents in mice. J. Clin. Invest. 134, e178250 (2024).","journal-title":"J. Clin. Invest."},{"key":"1302_CR83","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/s41591-018-0015-9","volume":"24","author":"K Cl\u00e9ment","year":"2018","unstructured":"Cl\u00e9ment, K. et al. MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency. Nat. Med. 24, 551\u2013555 (2018).","journal-title":"Nat. Med."},{"key":"1302_CR84","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1056\/NEJMoa1512693","volume":"375","author":"P K\u00fchnen","year":"2016","unstructured":"K\u00fchnen, P. et al. Proopiomelanocortin deficiency treated with a melanocortin-4 receptor agonist. N. Engl. J. Med. 375, 240\u2013246 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1302_CR85","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1021\/acs.jmedchem.2c02012","volume":"66","author":"MR Garnsey","year":"2023","unstructured":"Garnsey, M. R. et al. Discovery of the potent and selective MC4R antagonist PF-07258669 for the potential treatment of appetite loss. J. Med. Chem. 66, 3195\u20133211 (2023).","journal-title":"J. Med. Chem."},{"key":"1302_CR86","doi-asserted-by":"publisher","first-page":"4921","DOI":"10.1172\/JCI138392","volume":"130","author":"X Zhu","year":"2020","unstructured":"Zhu, X., Callahan, M. F., Gruber, K. A., Szumowski, M. & Marks, D. L. Melanocortin-4 receptor antagonist TCMCB07 ameliorates cancer- and chronic kidney disease-associated cachexia. J. Clin. Invest. 130, 4921\u20134934 (2020).","journal-title":"J. Clin. Invest."},{"key":"1302_CR87","doi-asserted-by":"publisher","DOI":"10.1172\/JCI181305","volume":"135","author":"X Zhu","year":"2024","unstructured":"Zhu, X. et al. Melanocortin-4 receptor antagonist TCMCB07 alleviates chemotherapy-induced anorexia and weight loss in rats. J. Clin. Invest. 135, e181305 (2024).","journal-title":"J. Clin. Invest."},{"key":"1302_CR88","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.tem.2017.01.003","volume":"28","author":"AR Moschen","year":"2017","unstructured":"Moschen, A. R., Adolph, T. E., Gerner, R. R., Wieser, V. & Tilg, H. Lipocalin-2: a master mediator of intestinal and metabolic inflammation. Trends Endocrinol. Metab.28, 388\u2013397 (2017).","journal-title":"Trends Endocrinol. Metab."},{"key":"1302_CR89","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nature21697","volume":"543","author":"I Mosialou","year":"2017","unstructured":"Mosialou, I. et al. MC4R-dependent suppression of appetite by bone-derived lipocalin 2. Nature 543, 385\u2013390 (2017).","journal-title":"Nature"},{"key":"1302_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22361-3","volume":"12","author":"B Olson","year":"2021","unstructured":"Olson, B. et al. Lipocalin 2 mediates appetite suppression during pancreatic cancer cachexia. Nat. Commun. 12, 2057 (2021).","journal-title":"Nat. Commun."},{"key":"1302_CR91","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-73372-x","volume":"17","author":"JL Seiler","year":"2026","unstructured":"Seiler, J. L. et al. Dual activation of MC3R and MC4R drives weight loss and reduces food intake in male primates with obesity. Nat. Commun. 17, 4808 (2026).","journal-title":"Nat. Commun."},{"key":"1302_CR92","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48971-1","volume":"15","author":"Q Sun","year":"2024","unstructured":"Sun, Q. et al. Area postrema neurons mediate interleukin-6 function in cancer cachexia. Nat. Commun. 15, 4682 (2024).","journal-title":"Nat. Commun."},{"key":"1302_CR93","doi-asserted-by":"publisher","DOI":"10.1126\/science.adm8857","volume":"388","author":"XA Zhu","year":"2025","unstructured":"Zhu, X. A. et al. A neuroimmune circuit mediates cancer cachexia-associated apathy. Science 388, eadm8857 (2025).","journal-title":"Science"},{"key":"1302_CR94","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.neuron.2020.11.010","volume":"109","author":"C Zhang","year":"2021","unstructured":"Zhang, C. et al. Area postrema cell types that mediate nausea-associated behaviors. Neuron 109, 461\u2013472 (2021).","journal-title":"Neuron"},{"key":"1302_CR95","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1146\/annurev-physiol-021115-104948","volume":"79","author":"SM Sternson","year":"2017","unstructured":"Sternson, S. M. & Eiselt, A. K. Three pillars for the neural control of appetite. Annu. Rev. Physiol. 79, 401\u2013423 (2017).","journal-title":"Annu. Rev. Physiol."},{"key":"1302_CR96","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1159\/000369072","volume":"100","author":"SM Sternson","year":"2014","unstructured":"Sternson, S. M. & Atasoy, D. Agouti-related protein neuron circuits that regulate appetite. Neuroendocrinology 100, 95\u2013102 (2014).","journal-title":"Neuroendocrinology"},{"key":"1302_CR97","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/s42255-022-00657-y","volume":"4","author":"L Steuernagel","year":"2022","unstructured":"Steuernagel, L. et al. HypoMap \u2014 a unified single-cell gene expression atlas of the murine hypothalamus. Nat. Metab. 4, 1402\u20131419 (2022).","journal-title":"Nat. Metab."},{"key":"1302_CR98","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/s41366-021-01025-8","volume":"46","author":"M Laughlin","year":"2022","unstructured":"Laughlin, M. et al. Neuroimaging and modulation in obesity and diabetes research: 10th anniversary meeting. Int. J. Obes. 46, 718\u2013725 (2022).","journal-title":"Int. J. Obes."},{"key":"1302_CR99","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1126\/science.1144599","volume":"317","author":"IS Farooqi","year":"2007","unstructured":"Farooqi, I. S. et al. Leptin regulates striatal regions and human eating behavior. Science 317, 1355 (2007).","journal-title":"Science"},{"key":"1302_CR100","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nature06212","volume":"450","author":"RL Batterham","year":"2007","unstructured":"Batterham, R. L. et al. PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans. Nature 450, 106\u2013109 (2007).","journal-title":"Nature"},{"key":"1302_CR101","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.cmet.2023.02.015","volume":"35","author":"S Edwin Thanarajah","year":"2023","unstructured":"Edwin Thanarajah, S. et al. Habitual daily intake of a sweet and fatty snack modulates reward processing in humans. Cell Metab. 35, 571\u2013584 (2023).","journal-title":"Cell Metab."},{"key":"1302_CR102","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1002\/hbm.23462","volume":"38","author":"P Geha","year":"2017","unstructured":"Geha, P., Cecchi, G., Todd Constable, R., Abdallah, C. & Small, D. M. Reorganization of brain connectivity in obesity. Hum. Brain Mapp. 38, 1403\u20131420 (2017).","journal-title":"Hum. Brain Mapp."},{"key":"1302_CR103","doi-asserted-by":"publisher","first-page":"14346","DOI":"10.1523\/JNEUROSCI.3323-10.2010","volume":"30","author":"PC Fletcher","year":"2010","unstructured":"Fletcher, P. C. et al. Distinct modulatory effects of satiety and sibutramine on brain responses to food images in humans: a double dissociation across hypothalamus, amygdala, and ventral striatum. J. Neurosci. 30, 14346\u201314355 (2010).","journal-title":"J. Neurosci."},{"key":"1302_CR104","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1017\/S0033291720001440","volume":"51","author":"ML Westwater","year":"2021","unstructured":"Westwater, M. L. et al. Dissociable hormonal profiles for psychopathology and stress in anorexia and bulimia nervosa. Psychol. Med. 51, 2814\u20132824 (2021).","journal-title":"Psychol. Med."},{"key":"1302_CR105","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.cmet.2007.11.007","volume":"6","author":"HJ Grill","year":"2007","unstructured":"Grill, H. J., Skibicka, K. P. & Hayes, M. R. Imaging obesity: fMRI, food reward, and feeding. Cell Metab. 6, 423\u2013425 (2007).","journal-title":"Cell Metab."},{"key":"1302_CR106","unstructured":"Bullmore, E. T. The Inflamed Mind: A Radical New Approach to Depression (Short Books, 2019)."},{"key":"1302_CR107","first-page":"37","volume":"3","author":"J Illman","year":"2005","unstructured":"Illman, J. et al. Are inflammatory cytokines the common link between cancer-associated cachexia and depression? J. Support. Oncol. 3, 37\u201350 (2005).","journal-title":"J. Support. Oncol."},{"key":"1302_CR108","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/pon.4512","volume":"27","author":"D Wasley","year":"2018","unstructured":"Wasley, D. et al. Patients with established cancer cachexia lack the motivation and self-efficacy to undertake regular structured exercise. Psychooncology 27, 458\u2013464 (2018).","journal-title":"Psychooncology"},{"key":"1302_CR109","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/jcsm.12286","volume":"9","author":"M Maldonado","year":"2018","unstructured":"Maldonado, M. et al. The habenula as a novel link between the homeostatic and hedonic pathways in cancer-associated weight loss: a pilot study. J. Cachexia Sarcopenia Muscle 9, 497\u2013504 (2018).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"1302_CR110","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.13742","volume":"16","author":"E Simoes","year":"2025","unstructured":"Simoes, E. et al. Cachexia alters central nervous system morphology and functionality in cancer patients. J. Cachexia Sarcopenia Muscle 16, e13742 (2025).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"1302_CR111","doi-asserted-by":"publisher","first-page":"106123","DOI":"10.1016\/j.bbi.2025.106123","volume":"130","author":"K Conn","year":"2025","unstructured":"Conn, K. et al. Cachexia in mice blunts improved cognitive flexibility induced by calorie restriction. Brain Behav. Immun. 130, 106123 (2025).","journal-title":"Brain Behav. Immun."},{"key":"1302_CR112","doi-asserted-by":"publisher","first-page":"6044","DOI":"10.1016\/j.cell.2025.07.016","volume":"188","author":"A Garrett","year":"2025","unstructured":"Garrett, A. et al. Vagal blockade of the brain\u2013liver axis deters cancer-associated cachexia. Cell 188, 6044\u20136063 (2025).","journal-title":"Cell"},{"key":"1302_CR113","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1038\/s41586-025-10028-8","volume":"650","author":"HK Wei","year":"2026","unstructured":"Wei, H. K. et al. Tumour\u2013brain crosstalk restrains cancer immunity via a sensory\u2013sympathetic axis. Nature 650, 1007\u20131016 (2026).","journal-title":"Nature"},{"key":"1302_CR114","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.ccell.2026.01.014","volume":"44","author":"X Shi","year":"2026","unstructured":"Shi, X. et al. Tumor\u2013immune\u2013neural circuit disrupts energy homeostasis in cancer cachexia. Cancer Cell 44, 949\u2013964 (2026).","journal-title":"Cancer Cell"},{"key":"1302_CR115","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.cmet.2016.10.010","volume":"24","author":"TR Flint","year":"2016","unstructured":"Flint, T. R. et al. Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity. Cell Metab. 24, 672\u2013684 (2016).","journal-title":"Cell Metab."},{"key":"1302_CR116","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1006\/bbrc.1997.7622","volume":"240","author":"Y Zhang","year":"1997","unstructured":"Zhang, Y. et al. The leptin receptor mediates apparent autocrine regulation of leptin gene expression. Biochem. Biophys. Res. Commun. 240, 492\u2013495 (1997).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1302_CR117","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37169-6","volume":"14","author":"RA Saxton","year":"2023","unstructured":"Saxton, R. A. et al. Structural insights into the mechanism of leptin receptor activation. Nat. Commun. 14, 1797 (2023).","journal-title":"Nat. Commun."},{"key":"1302_CR118","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41574-025-01184-y","volume":"22","author":"RR Fan","year":"2025","unstructured":"Fan, R. R., Beckham, J. D. & Rajagopalan, K. N. Leptin and melanocortin signalling in the response to infection. Nat. Rev. Endocrinol. 22, 92\u2013101 (2025).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1302_CR119","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.2337\/dc26-S002","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes 2. Diagnosis and classification of diabetes: standards of care in diabetes\u20132026. Diabetes Care 49, S27\u2013S49 (2026).","journal-title":"Diabetes Care"},{"key":"1302_CR120","unstructured":"National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. NICE https:\/\/www.nice.org.uk\/guidance\/ng28\/chapter\/Initial-medicines (2026)."},{"key":"1302_CR121","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1111\/jgs.70399","volume":"74","author":"AA Cohen","year":"2026","unstructured":"Cohen, A. A. & Picard, M. Potential risks of blocking GDF15-based brain energy sensing. J. Am. Geriatr. Soc. 74, 1516\u20131519 (2026).","journal-title":"J. Am. Geriatr. Soc."}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01302-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01302-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01302-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:02:21Z","timestamp":1790010141000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01302-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":121,"alternative-id":["1302"],"URL":"https:\/\/doi.org\/10.1038\/s41574-026-01302-4","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"26 August 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.P.C. has filed a patent on therapeutic targeting of GDF15\u2013GFRAL. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}